Mechanisms of biliary excretion of lithocholate-3-sulfate in Eisai hyperbilirubinemic rats (EHBR)

• Published in: Digestive diseases and sciences Vol. 40; no. 8; p. 1792
• Main Authors: Takikawa, H, Nishikawa, K, Sano, N, Yamanaka, M, Horie, T
• Format: Journal Article
• Language: English
• Published: United States 01.08.1995
• Subjects: Animals; Bile - metabolism; Colchicine - pharmacology; Hyperbilirubinemia - metabolism; Indocyanine Green - pharmacology; Lithocholic Acid - analogs & derivatives; Lithocholic Acid - metabolism; Male; Pravastatin - pharmacology; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Sulfobromophthalein - analogs & derivatives; Sulfobromophthalein - pharmacology; Taurocholic Acid - pharmacology
• ISSN: 0163-2116
• DOI: 10.1007/bf02212704

Biliary excretion of lithocholate-3-sulfate is markedly impaired in EHBR. To examine the mechanism of biliary lithocholate-3-sulfate excretion in EHBR, the effects of colchicine treatment, a vesicular transport inhibitor, and infusion of taurocholate and organic anions were studied in EHBR and Sprague-Dawley rats. Colchicine treatment and taurocholate infusion had no effect of biliary lithocholate-3-sulfate excretion in EHBR, suggesting that biliary lithocholate-3-sulfate excretion is not mediated by the vesicular transport or by the bile acid excretory pathway. In control Sprague-Dawley rats, both sulfobromophthalein and dibromosulfophthalein infusion inhibited biliary lithocholate-3-sulfate excretion. In contrast, in EHBR dibromosulfophthalein infusion inhibited biliary lithocholate-3-sulfate excretion but BSP infusion did not. Indocyanine green and pravastatin infusion did not affect biliary lithocholate-3-sulfate excretion but pravastatin infusion had no effect in EHBR. These findings indicate that, whether physiologically important or not, two of more excretory pathways for organic anions exist at the canalicular membrane other than the ATP-dependent one.